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Abstract Prion disease is a neurodegenerative malady,
which is believed to be transmitted via a prion protein in its
abnormal conformation (PrP
Sc). Previous studies have
failed to demonstrate that prion disease could be induced in
wild-type animals using recombinant prion protein (rPrP)
produced in Escherichia coli. Here, we report that prion
infectivity was generated in Syrian hamsters after inocu-
lating full-length rPrP that had been converted into the
cross-b-sheet amyloid form and subjected to annealing.
Serial transmission gave rise to a disease phenotype with
highly unique clinical and neuropathological features.
Among them were the deposition of large PrP
Sc plaques in
subpial and subependymal areas in brain and spinal cord,
very minor lesioning of the hippocampus and cerebellum,
and a very slow progression of disease after onset of
clinical signs despite the accumulation of large amounts of
PrP
Sc in the brain. The length of the clinical duration is
more typical of human and large animal prion diseases,
than those of rodents. Our studies establish that transmis-
sible prion disease can be induced in wild-type animals by
inoculation of rPrP and introduce a valuable new model of
prion diseases.
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Abbreviations
PrP
C Normal cellular isoform of the prion protein
PrP
Sc Abnormal, disease-associated isoform of the
prion protein
rPrP Recombinant PrP
PMCA Protein misfolding cyclic ampliﬁcation
TSE Transmissible spongiform encephalopathy
BH Brain homogenate
NBH Normal brain homogenate
PK Proteinase K
BSA Bovine serum albumin
LMW Low molecular weight
Introduction
Recent years have witnessed signiﬁcant progress in pro-
viding strong support to the protein-only hypothesis that
postulates that the prion diseases are transmitted via a
prion protein that acquires an infectious self-replicating
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Sc)[ 26]. Previously, amyloid ﬁbrils
prepared in vitro from truncated recombinant PrP (rPrP)
[4] were shown to induce transmissible disease in trans-
genic mice that express the same truncated cellular isoform
of the prion protein (PrP
C) at high levels [20]. However,
the origin of transmissible prions in transgenic lines has
been disputed due to concerns that the mice expressing
PrP
C at high levels are prone to neurological disorders with
undetectably low levels of infectivity. While these con-
cerns have been addressed [9], the objective of inducing
prion disease in wild-type animals with rPrP still represents
a great challenge.
Using an alternative approach that involves protein
misfolding cyclic ampliﬁcation (PMCA) conducted in
crude brain homogenates, ampliﬁcation of PrP
Sc was shown
to be accompanied byan ampliﬁcationofinfectivity in vitro
[8]. PMCA was also used to successfully generate prion
infectivity in vitro de novo from minimal components
including PrP
C and polyanion molecules [11]. Attempts to
replace PrP
C with rPrP in PMCA, however, have failed, as
rPrP was shown to inhibit PMCA reactions [24]. To date,
attempts to generate transmissible prion disease in wild-
type animals using rPrPs have not been successful despite
numerous attempts in which rPrP was converted into a
broad array of abnormal b-sheet rich conformations.
Here, we report that prion infectivity can be produced in
Syrian hamsters by inoculating full-length rPrP converted
into a cross-b-sheet amyloid conformation and subjected
to an annealing procedure [6]. The clinical disease, while
clearly recognizable as a transmissible spongiform
encephalopathy (TSE) infection, nevertheless exhibited a
highlyuniqueclinicalcourseandneuropathologicalfeatures
including large subependymal plaques, minor involvement
of cerebellum and hippocampus, but consistent lesioning in
thalamus and hypothalamus. Despite large amounts of PrP
Sc
found in the brains, the new disease is characterized by a
long clinical duration and very slow progression after the
ﬁrst clinical signsare observed,a featurethat ismore typical
of human and large animal TSEs, than those of rodents.
Materials and methods
Expression and puriﬁcation of PrP
Golden Syrian hamster full-length recombinant PrP
encompassing residues 23–231 (rPrP) was expressed and
puriﬁed according to the previously described procedure
[5] with minor modiﬁcations. To eliminate adduct forma-
tion and increase protein yield, 5 mM DTT instead of
10 mM b-mercaptoethanol was used to solubilize inclusion
bodies. Elution of PrP from the Ni-charged Sepharose resin
was performed with 200 mM Imidasole. Oxidative
refolding prior to HPLC was achieved by overnight dialysis
of IMAC-puriﬁed PrP into 8 M Urea, 100 mM Tris, pH
7.5. During the last 3 h of dialysis, 10 mM EDTA was
added to the dialysis buffer.
Formation of rPrP ﬁbrils
Lyophilized rPrP was dissolved in 6 M GdnHCl to prepare
a 3 mg/ml stock solution of rPrP. To form ﬁbrils, the rPrP
stock solution was diluted to a ﬁnal protein concentration
of 0.5 mg/ml and incubated at 37C in 20 mM sodium
acetate (pH 5.0), 1 M GdnHCl, 3 M urea, 150 mM NaCl,
10 mM EDTA for 4 days with continuous horizontal
shaking at 600 rpm. Amyloid formation was conﬁrmed by
increased Thioﬂavin T ﬂuorescence and electron micros-
copy [5]. Fibrils were dialyzed into 10 mM sodium acetate,
pH 5.0.
Annealing of ﬁbrils and inoculum preparation
The annealing was performed in two different ways: either
in the presence of normal brain homogenate (NBH) or
bovine serum albumin (BSA). The NBH used for annealing
of rPrP ﬁbrils was prepared from a 25-day-old Syrian
hamster, in a facility and with equipment that has never
been exposed to TSE agents. The brain was weighed, mixed
with nine parts of ice-cold PBS, pH 7.2, and homogenized
with a Branson Soniﬁer-450 tip sonicator until a homoge-
neous solution was formed (4 pulses of 15 s sonication with
15 s cooling on ice between the pulses). After incubation on
ice for 30 min, the homogenate was transferred to a new
tube leaving behind any crude material that had settled.
rPrP ﬁbrils at 0.1 mg/ml were heat-treated in PBS, pH
7.4, in the presence of 5% NBH or 5 mg/ml BSA (Sigma,
#A3294) and 0.1% Triton X-100 using the following pro-
cedure: 50 ll aliquots in thin-wall PCR tubes with domed
caps were placed into the PCR machine and subjected to 5
cycles of 1 min incubation at 80C followed by 1 min
incubation at 37C. The combined volume was immedi-
ately transferred to the animal facility for inoculation. To
verify the result of annealing, an aliquot of the inoculum
was supplemented with 100 mM Tris, pH 7.5, and sub-
jected to digestion with 50 lg/ml PK for 1 h at 37C. PK-
resistant material was detected by Western immunoblotting
with 3F4 antibody.
Bioassay
For the ﬁrst passage, weanling golden Syrian hamsters
were inoculated intracerebrally with the preparation of rPrP
ﬁbrils described above. Each animal was anesthetized with
interperitoneal pentobarbital before receiving 50 llo f
inoculum. Hamsters were observed daily for disease
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eight inoculated hamsters died intercurrently at 409 and
652 days postinoculation without signs of any disease. The
six remaining hamsters were still healthy at 661 days
postinoculation when they were euthanized and their brains
removed aseptically and saved for subsequent passage and
analysis.
For the second passage, 10% BHs prepared by sonica-
tion in PBS, pH 7.4, were dispersed by an additional 30 s
of sonication immediately before inoculation. Each ham-
ster received 50 ll of inoculum intracerebrally under
general anesthesia (2% O2/4 MAC isoﬂurane). After
inoculation, hamsters were observed daily for disease.
Proteinase K resistance assay
Brains were collected aseptically and cut in half with
disposable scalpels. One half was used to prepare 10%
BHs, while the second half was stored at -80C for
future analysis or ﬁxed in formalin for histopathology.
Homogenization was performed on ice, in PBS, pH 7.4,
with Sonics vibra cell VCX750 (Newtown, CT) tip
sonicator ﬁtted with a stepped microtip by 2 pulses of
30 s sonication with 30 s cooling on ice between the
pulses. An aliquot of 10% brain homogenate was mixed
with an equal volume of 4% sarcosyl in PBS, supple-
mented with 50 mM Tris, pH 7.5, and digested with
20 lg/ml PK for 30 min at 37C with 1,000 rpm shaking
(Eppendorf thermomixer). The reaction was stopped by
adding 2 mM PMSF and SDS sample buffer. Samples
were boiled for 10 min and loaded onto NuPAGE 12%
BisTris gels. After transfer to PVDF membrane, PrP was
detected with R1/R2 or 3F4 antibody, as indicated. To
achieve a comparable intensity of bands, samples without
PK were usually loaded at a 1:4 to 1:20 dilution as
indicated in the ﬁgure legends.
To analyze PK resistance as a function of PK concen-
tration, 10% BHs prepared by sonication in PBS (see
above) were diluted to 1% using 1% BH from healthy
hamsters in PBS, pH 7.5, 0.15 M NaCl, 1% Triton, and
0.25% SDS. Lyophilized Proteinase K (Sigma P6556) was
dissolved in the PK buffer containing 20 mM Tris, pH 7.5,
and 1 mM CaCl2, and the same buffer was used to prepare
serial dilutions of PK. Each aliquot of brain homogenate
was supplemented with the same volume, but increasing
concentration of PK, with the ﬁnal concentration ranging
from 0 to 2.5 mg/ml. After incubation at 37C for 1 h, the
reaction was stopped by addition of SDS-sample buffer and
boiling the samples for 10 min. Samples were loaded onto
NuPAGE 12% BisTris gels, transferred to PVDF mem-
brane, and detected with 3F4 antibody. To generate
average curves and standard deviation errors, all samples
were assayed at least twice.
Deglycosylation of PrP
Sc
Removal of N-linked glycans was performed as previously
described [10], using glycerol-free PNGase F and supplied
buffers (New England BioLabs). After termination of PK
digestion with 2 mM PMSF, the resulting 36 ll of digest
was supplemented with 4 llo f1 0 9 glycoprotein buffer
and heated at 95C for 10 min. After heat-treatment, 5 ll
of 109 G7 reaction buffer, 5 ll of 10% NP-40 and 3 llo f
PNGase F enzyme were added, and the samples were
incubated overnight at 37C. The next day, the samples
were boiled for 10 min in SDS sample buffer (Invitrogen)
and loaded onto NuPAGE 12% BisTris gels. After transfer
to PVDF, PrP was detected with 3F4 antibody.
Conformational stability assay
10% brain homogenates were incubated with various
concentrations of GdnHCl for 2 h at room temperature.
After incubation, all samples were diluted with 2% Sar-
cosyl and PBS to the ﬁnal concentration of GdnHCl of
0.4 M, digested with 20 lg/ml PK for 1 h at 37C with
shaking at 1,000 rpm (Eppendorf thermomixer). The
reaction was stopped by 2 mM PMSF. After addition of a
proteinase inhibitors cocktail (Complete, EDTA-free,
Roche), samples were precipitated by 0.3% sodium phos-
photungstate, pH 7.4 as previously described [27]. After
overnight incubation at 37C with shaking 1,000 rpm
(Eppendorf thermomixer), samples were centrifuged for
30 min at 13,000 rpm (accuSpin microR centrifuge, Fisher
Scientiﬁc). The pellet was resuspended in 0.2% Sarcosyl/
PBS, followed by addition of SDS sample buffer and
shaking for 15 min at 99C, 1,000 rpm. Samples were
loaded into NuPAGE 12% BisTris gels, transferred to
PVDF membrane, and detected with 3F4 antibody. Signal
intensities were calculated using WCIF ImageJ. The
experimental data were ﬁtted using a two-state model and
C50 values calculated from ﬁtting parameters. To generate
average values and standard deviation errors, all samples
were assayed twice.
Protein misfolding cyclic ampliﬁcation
Substrate was prepared following the protocol kindly pro-
vided by J. Castilla. Healthy hamsters were euthanized and
immediately perfused with PBS, pH 7.4, supplemented
with 5 mM EDTA. Brains were dissected, 10% brain
homogenate (w/v) was prepared using ice-cold conversion
buffer and glass/Teﬂon tissue grinders cooled on ice and
attached to a constant torque homogenizer (Heidolph
RZR2020). The brains were ground at low speed until
homogeneous, then 5 additional strokes completed the
homogenization. The composition of conversion buffer
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2?- and Mg
2?-free
PBS, pH 7.5, supplemented with 0.15 M NaCl, 1.0% Tri-
ton, and 1 tablet of complete protease inhibitors cocktail
(Roche, Cat# 1836145) per 50 ml of conversion buffer.
The resulting 10% normal BH in conversion buffer was
used as the substrate in PMCA reactions. To prepare seeds,
10% scrapie BH in PBS was diluted 100-fold in the con-
version buffer and 10 ll of the dilution were used to seed
90 ll of NBH in PMCA. Samples in 0.2 ml thin-wall PCR
tubes were placed in a ﬂoating rack inside Misonix-3000
cup-horn sonicator, ﬁlled with 300 ml water. Two coils of
rubber tubing attached to a circulating water bath were
installed for maintaining 37C inside the sonicator cham-
ber. The standard sonication program consisted of 40 s
sonication pulses delivered at 80% efﬁciency applied every
hour during a 48-h period.
Brain homogenates from the ﬁrst passage animals were
subjected to a single round of PMCA in an attempt to
increase the sensitivity of detection. In this case, the BH
served both as seed and as substrate for the ampliﬁcation. A
half brain from each animal (non-perfused) was homoge-
nized in the conversion buffer and aliquots of 100 ll were
subjected to 40 s sonication pulses applied every hour
during 48-h period as described above.
To analyze production of PK-resistant PrP material in
PMCA, 15 ll of the sample was supplemented with 2.5 ll
SDS and 2.5 ll PK, to the a ﬁnal concentration of SDS and
PK of 0.25% and 50 lg/ml, respectively, followed by
incubation at 37C for 1 h. The digestion was terminated
by addition of SDS-sample buffer and boiling for 10 min.
Samples were loaded onto NuPAGE 12% BisTris gels,
transferred to PVDF membrane, and detected with 3F4
antibody.
Histopathological studies
Tissues from three diseased hamsters from the second
passage of the NBH-annealed ﬁbril preparation, four same
age controls that had been inoculated with BHs from the
uninoculated same age controls of the ﬁrst passage, and
three uninoculated age-matched controls from the cohort of
animals used for the second passage were examined. For-
malin ﬁxed brain halves divided at the midline (right
hemisphere), spinal cord, and internal organs, including
tongue, testis, fat tissue, intestine at different levels, stom-
ach, spleen, liver, pancreas, kidney, bladder, adrenals, heart,
lung, trachea, skin, hind leg muscle, salivary and mesenteric
lymph nodes, thymus, and sciatic nerve were processed for
conventional stains including hematoxylin–eosin and luxol
fast blue-nuclear fast red, Alcian-blue and Periodic acid
Schiff (PAS), as well as for immunohistochemistry for PrP,
using the monoclonal anti-PrP antibody 3F4 (1:1000,
Covance, Berkeley, CA, USA), and monoclonal anti-glial
ﬁbrillar acidic protein (GFAP; 1:3000, Dako, Glostrup,
Denmark). Blocks were treated in formic acid (96%) prior
to embedding in parafﬁn. For detection of disease-associ-
ated PrP, we applied a pretreatment of 30-min hydrated
autoclaving at 121C followed by 5 min in 96% formic
acid. We evaluated all tissues for the presence of inﬂam-
mation and PrP immunoreactivity, and the brain for the
presence of spongiform change and degree of gliosis.
Degree of spongiform change, neuronal loss and gliosis,
and intensity of PrP immunostaining was semiquantita-
tively evaluated (0 none, 1 mild, 2 moderate, and 3 severe).
Lesion proﬁles were obtained by averaging scores of
spongiform change, neuronal loss, and gliosis for each
anatomical region and animal group [25]. For ultrastructural
investigation, small samples of spinal cord periaqueductal
regions obtained by needle biopsy from the parafﬁn block,
were deparafﬁnized, ﬁxed in glutaraldehyde and embedded
in epoxy resin. Semi-thin sections were cut at a thickness of
0.3–0.5 lm and were stained with toluidine blue. Ultrathin
sections of 80–90 nm were analyzed with a Zeiss electron
microscope. In addition, we compared brain pathology with
three Syrian hamsters (Harlan, WI) that had been infected
by intracranial injection with 10% (w/v) scrapie brain
homogenate (263K strain) and that showed clinical evi-
dence of disease.
Results
De novo generation of PrP
Sc in wild-type animals
Full-length golden Syrian hamster rPrP was converted into
amyloid ﬁbrils and subjected to annealing prior to inocu-
lation [5, 6]. Previously we showed that annealing (heating
to 80C in the presence of normal brain homogenate
(NBH)) extends the short proteinase K (PK)-resistant
region in rPrP ﬁbrils encompassing residues 152/162–231
to residues *97–231 [5, 6]. The annealing was performed
in the presence of NBH prepared from 25-day-old golden
Syrian hamsters or with bovine serum albumin (BSA). The
NBH-assisted annealing produced a 16 kDa PK-resistant
band, whereas in BSA-assisted annealing a 16 kDa band
was not detectable (Fig. 1a). All experiments on expression
and puriﬁcation of rPrP, its conversion into ﬁbrils,
annealing and preparation of inocula were performed in a
facility and with equipment that have never been exposed
to TSEs (concerns regarding possible cross-contamination
are addressed in SI).
The NBH- and BSA-annealed rPrP ﬁbrils were inocu-
lated intracerebrally into golden Syrian hamsters along
with the following controls: a-rPrP-monomer mock-
annealed with NBH, mock-annealed NBH alone, and non-
annealed rPrP ﬁbrils. The ﬂow chart outlining primary
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None of the animals developed any signs of disease for up
to 661 days after inoculation when they were euthanized
(Table 1). One hamster inoculated with NBH-annealed
ﬁbrils (animal #36798) showed PK-resistant PrP with a
band-shift typical for PrP
Sc (Fig. 1b). One animal inocu-
lated with BSA-annealed rPrP amyloid (animal #36787)
also showed PK-resistance, however, with atypical, low
molecular weight (LMW) PK-resistant bands (Fig. S1). No
PK-resistant PrPs were found in animals inoculated with
any of the controls or in uninoculated age-matched controls
(Table 1, Fig. S2).
Brain homogenates (BHs) from six animals that repre-
sent three groups were selected for a second passage: (1)
BH with PrP
Sc (animal #36798) and BH that lacked
detectible PrP
Sc (animal #36793), both from the group
inoculated with NBH-annealed ﬁbrils; (2) BH with LMW
PK-resistant (animal #36787) and BH that lacks detectible
PK-resistant PrPs (animal #36788), both from the group
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Fig. 1 De novo generation of PrP
Sc in Syrian hamsters. a Western
blotting of rPrP ﬁbrils annealed in the presence of NBH or BSA.
NBH-annealed ﬁbrils showed a PK-resistant product of 16 kDa.
Undigested samples were loaded at 1/20th the amount of the digested
samples. b Western blotting of BHs from animals inoculated with
NBH-annealed ﬁbrils. Animal #36798 showed PK-resistant PrP
Sc
with a characteristic band shift. c Western blotting of BHs from
animals inoculated with BH from animal #36798. Without PK
treatment, 1/10th of a sample was loaded. d Western blotting of BHs
from animals inoculated with 10% BH from animal #36793.
Undigested sample was loaded at 1/10th the amount of the digested
samples. e Western blotting of BHs from animals inoculated with
NBH-annealed ﬁbrils. BHs were subjected to a single round of PMCA
that consisted of 40-s sonication pulses applied every hour during a
48-h period, where each sample was its own substrate. Samples in a,
b, e were treated with 50 lg/ml PK, and samples in c and d with
20 lg/ml PK. 3F4 antibody was used for a, c–e and R1 antibody was
used for b
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Fig. 2 A ﬂow chart outlining the serial passages of NBH- or BSA-
annealed rPrP ﬁbrils. Animal numbers are shown in the boxes. The
animals that produced PrP
Sc detectible by Western blotting are in dark
gray boxes, and the animals where PrP
Sc was detected after a single
round of PMCA are in light gray boxes. Animal #36787 showed
atypical, low molecular weight PK-resistant bands
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123inoculated with BSA-annealed ﬁbrils; and (3) two unin-
oculated age-matched controls (Table 1, Fig. 2). All
hamsters inoculated with BH of animal #36798 from the
NBH-annealed group showed clinical signs of disease at
481 ± 4 days after inoculation (Table 1). The clinical
signs and progression were highly unique (detail descrip-
tion is in SI, movie clips 1–4). The clinical disease
progressed unusually slowly, therefore one animal
(#43902) was euthanized 42 days after clinical onset to
establish whether this was indeed a TSE infection. The
conditions of the remaining animals deteriorated very
slowly and all were euthanized from 80 to 120 days after
onset of clinical symptoms before any had reached a ter-
minal moribund stage. All BHs from this group including
animal #43902 showed large amounts of PK-resistant PrP
Sc
(Fig. 1c). As judged from Western blotting, the amount of
PK-resistant PrP
Sc exceeded by several fold the amount of
PrP
Sc in 263K-inoculated hamsters at the terminal stage
(Fig. S3).
Surprisingly, all animals inoculated with BH of animal
#36793 that received NBH-annealed ﬁbrils also developed
clinical disease, however, at an older age (565 ± 14 days
after inoculation, Table 1). This group had the same
symptoms as those inoculated with the BH of animal
#36798 and showed similarly large amounts of PK-resistant
PrP
Sc in their brains (Fig. 1d). Puzzled by these results, we
went back and analyzed PK-resistance in BHs of animals
that received NBH-annealed ﬁbrils again. Prior to PK-
digestion, however, 10% BHs were subjected to a sonica-
tion procedure similar to a single round of protein
misfolding cyclic ampliﬁcation (PMCA) that consisted of
48 cycles. The BH of animal #36793 that was selected for
the second passage showed a small amount of PK-resistant
PrP
Sc after sonication (Fig. 1e, Fig. S4a). This small, ini-
tially undetectable quantity of PK-resistant PrP
Sc cannot be
due to horizontal transmission of prions from the animal
#36798, because these two animals were housed in different
cages. When the conditions for PMCA reaction were opti-
mized for the newly generated TSE strain, two additional
BHs (#36799 and #36791), one from the group inoculated
with NBH-annealed ﬁbrils and another from the group
inoculated with BSA-annealed ﬁbrils showed PK-resistant
PrP
Sc (Fig. S4b). In summary, 3 out of 6 animals inoculated
with NBH-annealed ﬁbrils showed infectivity/PrP
Sc as
detected by either second passage or by a single-round
PMCA. PMCA has been used to generate prion infectivity
de novo from normal brain homogenate but only after 10
rounds of 240 sonication cycles per round. After 50 days of
sonication only 1 BH out of 10 showed PrP
Sc [2]. In con-
trast, we used only a single round of 48 cycles, where seed
and substrate were in the same homogenate, and where our
objective was to increase sensitivity of detection. There was
no possibility of de novo synthesis as born out by controls.
None of the BHs from any of the negative control groups
Table 1 Bioassay of rPrP amyloid ﬁbrils in golden Syrian hamsters
Inoculum ns/nt
a nPK-res/nt
b Clinical onset
(days PI)
Euthanized
at days PI
NBH-annealed rPrP ﬁbrils 0/6 3
d/6 – 661
BSA-annealed rPrP ﬁbrils 0/7 2
e/7 – 661
None (age-matched controls) 0/9 0/9 – 661
f
Mock-annealed NBH 0/7 0/7 – 660
a-rPrP-monomer mock-annealed with NBH 0/8 0/8 – 660
rPrP-ﬁbrils
c 0/7 0/7 – 690, 704, 5 at 732
2nd Passage: 10% BH from age-matched control #1 0/5 0/5 – 661
2nd Passage: 10% BH from age-matched control #2 0/5 0/5 – 661
2nd Passage of NBH-annealed ﬁbrils (from #36798) 8/8 8/8 481 ± 4 523, 561, 561, 568,
574, 586, 586, 601
2nd Passage of NBH-annealed ﬁbrils (from #36793) 7/7 7/7 565 ± 14 1 at 655, 6 at 661
2nd Passage of BSA-annealed ﬁbrils (LMW PK-resistant, from #36787) 0/7 6/7 – 661
2nd Passage of BSA-annealed ﬁbrils (PK-sensitive, from # 36788) 0/7 0/7 – 661
a Number of animals with clinical signs over the total number of animals survived to the end of the experiment
b Number of animals with PK-resistant PrP in BHs over the total number of animals survived to the end of the experiment
c The rPrP ﬁbrils (S-type) were produced as previously described [22]
d In one BH PK-resistant PrP
Sc was found by PK digestion assay, and in two additional BHs PK-resistant PrP
Sc appeared after a single round of
PMCA
e One BH showed PK-resistant PrP with atypical low molecular weight bands; this and one additional BH showed PK-resistant PrP
Sc after a
single round of PMCA
f Age-matched control animals were not inoculated, but euthanized at the age matching the age of corresponding inoculated groups
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123that included uninoculated age-matched controls, second
passages of two uninoculated age-matched controls,
animals inoculated with mock-annealed NBH, or with
a-rPrP-monomer mock-annealed with NBH produced any
PK-resistant PrP after PMCA (Table 1, Figs. S2, S4b).
None of the hamsters from the second passage of BSA-
annealed ﬁbrils developed clinical disease before they were
euthanized at 661 days after inoculation. Despite the lack
of clinical signs, 6 out of 7 hamsters inoculated with LMW
PK-resistant BH showed PK-resistant PrP in amounts
similar to those found at the terminal stage of 263K-inoc-
ulated hamsters and with a band-shift typical for PrP
Sc
(Fig. S5a).
Unique biochemical features of the de novo generated
prions
Biochemical assays were employed to characterize the
newly generated TSE strain that was designated SSLOW
(Synthetic Strain Leading to OverWeight). While the PrP
Sc
glycosylation pattern of SSLOW appeared to be similar to
that of 263K, the PrP
Sc PK-resistant core was slightly
shorter in SSLOW (by *0.5–1 kDa) than in 263K, as
judged from the mobility after deglycosylation by PGNase
(Fig. 3a). The slightly shorter size was a characteristic
feature of PrP
Sc produced in the ﬁrst and second passage
of NBH-annealed ﬁbrils (Fig. 3a). The conformational
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Fig. 3 Biochemical characterization of the de novo generated prions.
a BHs from the ﬁrst (animal #36798) or second passage (animals
#43902 and #43908) of NBH-annealed ﬁbrils were treated with PK
and PNGase and analyzed by Western blotting. Arrows indicate the
center of the deglycosylated PrP
Sc from 263K-inoculated hamsters.
BH #43902 was loaded at 1/4th of the amount of 263K BH. b Western
blotting and the conformational stability proﬁles (iv) of the GdnHCl-
induced transitions of the NBH-annealed ﬁbrils (i), or PrP
Sc from ﬁrst
(ii) or second (iii) passage of NBH-annealed ﬁbrils. NBH-annealed
ﬁbrils (blue circles), PrP
Sc from ﬁrst passage (green square, animal
#36798), second passage (yellow, orange, brown,o rpink triangles—
animals #43902, 43904, 43908, or 43909), or 263K-inoculated
animals (red diamonds). Each BH was loaded onto the gel twice
and the data were averaged. c The ampliﬁcation kinetics for 263K or
PrP
Sc from second passage of NBH-annealed ﬁbrils (BH #43902) as
monitored by Western blotting during a single round of PMCA that
consisted of 100 cycles. Samples in a, b (ii and iii) were treated with
20 lg/ml PK; samples in c with 50 lg/ml PK; and samples in b (i)
with 2 lg/ml PK
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123stability assay revealed that the resistance of SSLOW to
GdnHCl-induced denaturation decreased gradually over the
course of serial transmission. The [GdnHCl]1/2 values were
4.1 ± 0.05 M, 3.0 ± 0.1 M, and 2.0 ± 0.2 M for the
NBH-annealed ﬁbrils used for inoculations, PrP
Sc from the
ﬁrst passage (animal # 36798), and PrP
Sc from the second
passage, respectively (Fig. 3b). After the second passage,
the [GdnHCl]1/2 values for SSLOW were similar to that of
263K (Fig. 3b). Despite similar conformational stabilities,
SSLOW had a much longer incubation time than 263K.
Furthermore, the yield of in vitro replication of SSLOW
was persistently lower than that of 263K, as judged from
the kinetics of PrP
Sc ampliﬁcation measured within a single
round of PMCA reactions (Fig. 3c). The resistance of PrP
Sc
to proteolytic digestion was similar for SSLOW and 263K
as evaluated by the assays conducted at increasing con-
centrations of PK (Fig. S6).
The deglycosylation with PGNase of the PK-resistant
PrP from the second passage of BSA-annealed ﬁbrils
revealed that the PK-resistant core was similar to that of
SSLOW strain being slightly shorter than the deglycosy-
lated PrP
Sc from 263K (Fig. S5b). While the similarity in
PK-resistant core suggests that the same strain is emerging
in animals inoculated with BSA-annealed ﬁbrils, it remains
to be determined whether a clinical disease will appear in a
third passage of BSA-annealed ﬁbrils.
SSLOW strain displays unique neuropathological
proﬁle
Histopathological studies of hamsters from the second
passage of NBH-annealed ﬁbrils revealed characteristic
signs of TSE infection including spongiform degeneration,
neuronal loss, reactive astrogliosis, and deposition of dis-
ease-associated PrP in the brains and spinal cords (Fig. 4,
Figs. S7, S8). No inﬂammatory changes or immunoreac-
tivity for disease-associated PrP were found in any
peripheral tissues examined (complete list of tissues is in
Methods). Spongiform change, neuronal loss, and reactive
astrogliosis were uniformly prominent in the thalamus,
caudate-putamen, brain stem, spinal cord, and deeper lay-
ers of frontal cortex. However, they were very mild in the
hippocampus and cerebellum (Fig. 4a, c–e, Fig. S7). In
contrast to animals infected with SSLOW strain, the brains
of 263K-infected hamsters showed uniform involvement of
the cerebellum, hippocampus and all layers of the frontal
cortex (Fig. 4a, c–e, Fig. S7).
The distribution and pattern of PrP immunostaining were
remarkably different for SSLOW- and 263K-infected brains
(Fig. 4b–e, Fig. S7). While both strains showed synaptic
immunoreactivity for PrP deposits, SSLOW-infected ani-
mals were characterized by more intensive perineuronal
deposits and large plaques with a diameter of 20–60 lmi n
the subpial, periventricular, and periaqueductal sube-
pendymal regions (Fig. 4f–h, Fig. S7, S8). In contrast,
263K-infected brains showed focal patchy or smaller pla-
que-like deposits with a diameter of 5–15 lm in gray and
white matter structures. Both strains displayed immunore-
activity in subependymal regions, whereas perivascular PrP
deposits were found only in hamsters infected by the 263K
strain. While synaptic and perineuronal immunoreactivity
showed anatomical variability between SSLOW-infected
animals, the most striking histopathological feature of
SSLOW strain was the uniform deposition of large plaques
in the subpial, periventricular, and periaqueductal sube-
pendymal regions spanning all locations including brain
and spinal cord (Fig. 4, Figs. S7, S8). These plaques stained
with Alcian blue and with PAS at their borders (Fig. S8).
Electron microscopy revealed that these plaques consist of a
loose meshwork of randomly orientated ﬁlaments of 10–
25 nm in diameter (Fig. 4j, k). Animals from control groups
lacked any spongiform degeneration or deposition of dis-
ease-associated PrP (Fig. S9).
Discussion
The current studies demonstrate that recombinant PrP in its
ﬁbrillar b-sheet rich conformation subjected to annealing
induces a transmissible form of prion disease in wild-type
animals. In the ﬁrst passage, NBH-annealed ﬁbrils were
found to seed formation of PrP
Sc in hamster brains, but
failed to cause clinical disease, which was only observed at
the second passage. The lack of symptomatic disease by
end of life is consistent with a very slow replication of
PrP
Sc and that the newly emerged strain is intrinsically
slow. Previous work has shown that the incubation period
of a prion disease can exceed the life span of an animal
even when induced by natural prion strains [13–16, 19]. In
classical studies by Dickinson et al. [13], mice inoculated
with high titers of certain strains of mouse-adapted scrapie
prions remained free of clinical symptoms for their entire
life span despite histopathological changes and accumula-
tion of PrP
Sc in their brains at the end of their life span.
Because incubation time, long or short, is an intrinsic
function of TSE strain, it cannot be used to deduce the
concentration of infectious material in the inoculum with-
out more knowledge of the dose response. A number of
lines of evidence in the current study suggest that the newly
generated strain that we call SSLOW is intrinsically very
slow. When the incubation time exceeds the life span of the
animal it may be difﬁcult to determine the actual trans-
mission rate because one can detect only those infections
that have progressed to a detectable endpoint by the end of
life. To increase the sensitivity at the endpoint, we
employed a single-round PMCA. Using this procedure,
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Sc was detected in two additional animals inoculated
with NBH-annealed ﬁbrils. We do not know whether or not
all of the animals from the ﬁrst passage would have proved
to be infected, had we carried all of them forward in a
second passage.
The apparent 50% efﬁciency of infection in animals
inoculated with NBH-annealed ﬁbrils could be attributed to
several factors. First, because rPrP ﬁbrils lack a GPI-anchor,
they do not attach to the cell surface as efﬁciently as
authentic PrP
Sc and, therefore, might display reduced ability
toinvadecellsandseedprionreplication.Second,rPrPﬁbrils
and PrP
Sc appear to have fundamentally different global
structures [29]. Because PrP
C might not be fully compatible
with the structure of rPrP ﬁbrils, seeding of PrP
C conversion
withrPrPﬁbrilsmightproceedthroughslowconformational
adaptation [3]. The gradual change in conformational sta-
bility during serial transmission observed here supports the
hypothesis of conformational adaptation. Previous studies
Fig. 4 SSLOW strain displays
unique neuropathological
proﬁle. a, b Lesion proﬁle (a)
and PrP immunopositivity score
(b) in hamsters inoculated with
SSLOW (2nd passage of NBH-
annealed ﬁbrils) or 263K. The
lesion proﬁle was obtained by
averaging the scores for
spongiform change, neuronal
loss, and gliosis for three
animals within each group.
c–e Comparison of spongiform
changes in the hippocampus
(c), thalamus (d), or cerebellum
(e) stained with hematoxylin
and eosin (upper panels) or anti-
PrP 3F4 antibody (lower panels)
in a representative hamsters
inoculated with SSLOW
(animal # 43902, left panels)o r
263K (right panels). f Low-
magniﬁcation (920) overview
of frontal cortex (enlarged at
9100 in right upper inset) and
caudate-putamen (enlarged at
9100 in right lower inset) using
immunostaining for disease-
associated PrP. g, h High-
magniﬁcation images (9400)
of PrP immunoreactive plaques
in the periventricular
subependymal region (g), and
synaptic and perineuronal PrP
immunoreactivity in the frontal
cortex (h). i Overview of PrP
immunostaining (950) of spinal
cord demonstrates prominent
plaque deposition (enlarged
right lower inset) in the midline
and in periaqueductal region.
j, k Electron microscopy of a
plaque from the periaqueductal
region from the spinal cord
(scale bar 10 lmi nj or 0.4 lm
in k)
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123on synthetic mouse prions revealed a similar trend, where
conformational stability of the de novo generated synthetic
strains was found to decrease gradually during their serial
transmission [9, 21]. The conformational adaptation could
involve a conformational switch within individual ﬁbrils
[23], where rPrP ﬁbrils with one global structure might
recruit PrP
C, elongate and give a rise to PrP
Sc with different
globalstructure.Third,aspostulatedbythe‘‘uniﬁedtheory’’
of prion propagation [28], efﬁcient replication of prions
appears to require cellular cofactors, such as RNAs [11, 12].
The 50% efﬁciency of the infection in the ﬁrst passage
indicates that the annealing protocol might not yet faithfully
mimic the interaction of rPrP with a co-factor for generating
authenticPrP
Scin vitro.ThefactthatPrP
Scwasfoundinboth
animal groups, inoculated either with NBH- or BSA-
annealed ﬁbrils, suggests that the role of NBH-annealing is
non-speciﬁc and that, perhaps, it plays a role of a stabilizer.
By analogy, numerous viruses must be stabilized with milk,
serum, albumin, or gelatin to survive inoculation.
The 50% transmission at ﬁrst passage is also consistent
with a very low titer of the active species in the original
inoculum. However, if one assumes that only a small
subpopulation of ﬁbrils is infectious, it would be difﬁcult to
explain a correlation between conformational stability of
rPrP ﬁbrils, which is a bulk property of ﬁbril preparations,
and the incubation times to disease observed in the previ-
ous study on synthetic prions [9].
One of the most remarkable features of the prion disease
causedbySSLOWstrainisitslongclinicaldurationafterthe
ﬁrstclinicalsignsareobserved.Infact,theactualdurationto
adeathendpointisnotknownastheanimals,whileseriously
compromised, were still mobile, eating and drinking at the
time of euthanasia. It is conceivable that animals may have
enduredlongerthan120 daysafterﬁrstclinicalsigns,ifthey
had not been euthanized. Such a long duration is more typ-
ical of human and large animal TSEs, than those of rodents.
The slow progression is surprising considering that large
amounts of PrP
Sc were already present at the initial stages of
clinical disease. Theslow progression may be attributableto
the very peculiar pattern of deposition of PrP
Sc which was
found predominantly in the form of large plaques. The PrP
Sc
deposition patterns and brain histopathology differed
prominently between SSLOW and 263K or other hamster
strains. One of the most intriguing features of the SSLOW
strain was the very minor involvement of the cerebellum
highlighting a unique neurotropism of this strain. Very mild
PrP
Sc deposition in the cerebellum correlated well with
apparent lack of the severe motor dysfunctions typical for
263K. The sparing of the hippocampus in SSLOW is
intriguing and reminiscent of sparing of the hippocampus in
the most common subtype (MM/MV-1) of human sporadic
Creutzfeldt–Jakob disease (CJD) [7, 25]. In contrast, the
large subpial and subependymal plaques were distinct not
only from plaque-like deposits in 263K scrapie of hamsters
but also from human TSEs with plaques including the Kuru
plaque variant (MV-2) of sporadic CJD or Gerstmann–
Straussler–Scheinker disease.
InsecondpassageofNBH-annealedﬁbrils,thetwogroups
of animals inoculated with BHs from #36793 and #36798
showed different incubation times to onset of disease. This
difference can be attributed to a lower infectivity titer in BH
from #36793, consistent with the substantially lower amount
of PK-resistant PrP
Sc in this brain. As judged from clinical
signs and biochemical assays, however, the same strain
appears to have emerged in both groups. Remarkably, in a
second passage of BSA-annealed ﬁbrils, PK-resistant PrP
showed a band shift identical to that of SSLOW PrP
Sc raising
the possibility that the same stain might emerge in serial
passages of two independently prepared inoculums: NBH- or
BSA-annealed ﬁbrils. The third passage of NBH- and BSA-
annealed ﬁbrils should clarify this question.
The conformational stability of SSLOW PrP
Sc that
formed inasecondpassagewasverysimilartothatof263K,
yet these two strains showed markedly different incubation
timesarguingthatfactorsotherthanconformationalstability
also contribute to the rate of prion replication. Nevertheless,
the substantially longer incubation time for SSLOW corre-
lated well with the lower yield of SSLOW replication in
PMCA as compared to 263K (Fig. 3c).
Much of the public health risk from TSE diseases
derives from their long asymptomatic incubation times.
During this period infected humans (or animals) appear
normal and their underlying disease is currently undetect-
able. Such individuals pose a real risk of spreading the
infection through invasive medical procedures or tissue or
blood donation. Variant CJD infections of humans het-
erozygous at the codon 129 of the prion gene may present
such a risk [18]. The SSLOW strain offers an experimental
model to investigate this problem.
In pursuing the objective of generating synthetic prions
in vitro, it is useful to consider how prions originate in the
natural environment. Spontaneous occurrence of transmis-
sible prion disease has never been documented in wild-type
rodents including golden Syrian hamsters or wild-type
mice, nor has prion disease occurred upon serial inocula-
tions of brain homogenates from old to young animals [17].
All experimental hamster or mouse strains have been
derived by serial transmission of TSE agents from species
with substantially longer life span than rodents. While other
neurodegenerative diseases can be triggered as a result of
proteostasis deﬁciency at old age [1], the genesis of trans-
missible prions appears to require a very speciﬁc trigger
and/or conditions that are much more peculiar than imbal-
ance of proteostasis. Surprisingly, the current study
suggests that transmissible prion disease can be induced by
a preparation of rPrP ﬁbrils, which appear to be
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123fundamentally different with respect to their global struc-
ture from PrP
Sc. One can speculate that only partial or
distant similarities between ﬁbrillar rPrP and PrP
Sc struc-
tures may be sufﬁcient for triggering conversion of PrP
C
into PrP
Sc by ﬁbrillar rPrP. We do not know whether the
emergence of highly efﬁcient prion strains in nature occurs
within a single life span or require evolution, adaptation,
and selection of PrP
Sc structures. Prion genesis in nature
might require a series of transmissions from animal to
animal as may have happened with Bovine Spongiform
Encephalopathy. In this regard, it would be interesting to
learn whether clinical disease appears in a third passage of
BSA-annealed ﬁbrils.
In summary, this work represents an important advance in
prion science, in that (i) it is the ﬁrst time that a wild-type
recombinant PrP has been shown to be able to induce a TSE
diseaseinawild-typeanimal;(ii)thediseasegeneratedbythe
in vitro refolded rPrP while clearly recognizable as a TSE
disease is unique in its clinical presentation, pathology, and
biochemistry and may prove of great interest. Because of its
uniquefeatures,theSSLOWstrainmayprovetobeavaluable
model foraddressinga numberofpuzzlingquestions ofprion
biology: what factors determine prion neurotropism; how
strain-speciﬁc PrP
Sc structures control the rate of prion repli-
cation;whyclinicaldiseasecouldprogressessoslowlydespite
large amounts of PrP
Sc deposition; and the physical nature of
toxic versus infectious PrP isoforms. Further studies on syn-
thetic prions will likely provide unique insights into the
genesis and evolution of natural prion strains.
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